Mitochondrial dysfunction in demyelinating diseases

Seminars in Pediatric Neurology

Volumn 20, Issue 3, 2013, Pages 194-201

  Carvalho, Karen S ^a,b  

^a ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA; MYELIN;

ADRENOLEUKODYSTROPHY; ARTICLE; AXONAL INJURY; CAUSAL ATTRIBUTION; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG TARGETING; HUMAN; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PATHOPHYSIOLOGY;

AXONS; DEMYELINATING DISEASES; DISEASE PROGRESSION; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MODELS, NEUROLOGICAL; MOLECULAR TARGETED THERAPY; MYELIN SHEATH; NEURONS; OLIGODENDROGLIA; OXIDATIVE STRESS;

EID: 84890196397     PISSN: 10719091     EISSN: 15580776     Source Type: Journal    
DOI: 10.1016/j.spen.2013.09.001     Document Type: Article

References (63)

1. Mahad D., Lassmann H., Turnbull D. Review: Mitochondria and disease progression in multiple sclerosis. Neuropathol Appl Neurobiol 2008, 34:577-589.
2. van Horssen J., Witte M.E., Ciccarelli O. The role of mitochondria in axonal degeneration and tissue repair in MS. Mult Scler 2012, 18:1058-1067.
3. Fourcade S., López-Erauskin J., Galino J., et al. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum Mol Genet 2008, 17:1762-1773.
4. Franklin R.J., French-Constant C. Remyelination in the CNS: From biology to therapy. Nat Rev Neurosci 2008, 9:839-855.
5. Kornek B., Storch M.K., Weissert R., et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000, 157:267-276.
6. Legido A., Tenembaum S., Katsetos C.D., et al. Autoimmune and postinfectious diseases. Child Neurology 2005, 557-657. Lippincott Williams & Wilkins, Philadelphia. (ed 7). J. Menkes, H. Sarnat, B. Maria (Eds.).
7. Finsterer J. Central nervous system manifestations of mitochondrial disorders. Acta Neurol Scand 2006, 114:217-238.
8. Lerman-Sagie T., Leshinsky-Silver E., Watemberg N., et al. White matter involvement in mitochondrial diseases. Mol Genet Metab 2005, 84:127-136.
9. Tang S., Wang J., Lee N.C., et al. Mitochondrial DNA polymerase gamma mutations: An ever expanding molecular and clinical spectrum. J Med Genet 2011, 48:669-681.
10. Yang J.L., Weissman L., Bohr V.A., et al. Mitochondrial DNA damage and repair in neurodegenerative disorders. DNA Repair 2008, 7:1110-1120.
11. Cortopassi G., Danielson S., Alemi M., et al. Mitochondrial disease activates transcripts of the unfolded protein response and cell cycle and inhibits vesicular secretion and oligodendrocyte-specific transcripts. Mitochondrion 2006, 6:161-175.
12. Schoenfeld R., Wong A., Silva J., et al. Oligodendroglial differentiation induces mitochondrial genes and inhibition of mitochondrial function represses oligodendroglial differentiation. Mitochondrion 2010, 10:143-150.
13. Deng W., Yue Q., Rosenberg P.A., et al. Oligodendrocyte excitotoxicity determined by local glutamate accumulation and mitochondrial function. J Neurochem 2006, 98:213-222.
14. Lee D., Gold R., Linker R.A., et al. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: Therapeutic modulation via fumaric acid esters. Int J Mol Sci 2012, 13:11783-11803.
15. Haider L., Fischer M.T., Frischer J.M., et al. Oxidative damage in multiple sclerosis lesions. Brain 2011, 134:1914-1924.
16. Holley J.E., Newcombe J., Winyard P.G., et al. Peroxiredoxin V in multiple sclerosis lesions: Predominant expression by astrocytes. Mult Scler 2007, 13:955-961.
17. Krupp L.B., Banwell B., Tenembaum S., et al. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007, 68(suppl 2):S7-S12.
18. Banwell B., Kennedy J., Sadovnick D., et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology 2009, 72:232-239.
19. Defresne P., Hollenberg H., Husson B., et al. Acute transverse myelitis in children: Clinical course and prognostic factors. J Child Neurol 2003, 18:401-406.
20. Tenembaum S., Chamoles N., Fejerman N. Acute disseminated encephalomyelitis: A long-term follow-up study of 84 pediatric patients. Neurology 2002, 59:1224-1231.
21. Banwell B. Pediatric multiple sclerosis. Curr Neurol Neurosci Rep 2004, 4:245-252.
22. Mikaeloff Y., Suissa S., Vallée L., et al. First episode of acute CNS inflammatory demyelination in childhood: Prognostic factors for multiple sclerosis and disability. J Pediatr 2004, 144:246-252.
23. Rosati G. The prevalence of multiple sclerosis in the world: An update. Neurol Sci 2001, 22:117-139.
24. Boiko A., Vorobeychik G., Paty D., et al. Early onset multiple sclerosis: A longitudinal study. Neurology 2002, 59:1006-1010.
25. Simone I.L., Carrara D., Tortorella C., et al. Course and prognosis in early-onset MS: Comparison with adult-onset forms. Neurology 2002, 59:1922-1928.
26. Dale R.C., de Sousa C., Chong W.K., et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000, 123:2407-2422.
27. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
28. Holmoy T., Vartdal F. The immunological basis for treatment of multiple sclerosis. Scand J Immunol 2007, 66:374-382.
29. Lassmann H. Cortical lesions in multiple sclerosis: Inflammation versus neurodegeneration. Brain 2012, 135:2904-2905.
30. Gold R., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
31. Korn T. Pathophysiology of multiple sclerosis. J Neurol 2008, 255(suppl 6):2-6.
32. Stadelmann C. Multiple sclerosis as a neurodegenerative disease: Pathology, mechanisms and therapeutic implications. Curr Opin Neurol 2011, 24:224-229.
33. Lassman H: Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci 2013 [Epub ahead of print].
34. Lisak R.P., Benjamins J.A., Bealmear B., et al. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for molecules associated with metabolism, signaling and regulation in central nervous system mixed glial cell cultures. J Neuroinflammation 2009, 6:4.
35. Taylor R.W., Turnbull D.M. Mitochondrial DNA mutations in human disease. Nat Rev Genet 2005, 6:389-402.
36. Lu F., Selak M., O'Connor J., et al. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J Neurol Sci 2000, 177:95-103.
37. Lu F., Selak M., O'Connor J., et al. Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol 2009, 177:193-204.
38. Trapp B.D., Stys P.K. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009, 8:280-291.
39. Kostic K., Zivkovic N., Stojanovic I. Multiple sclerosis and glutamate excitotoxicity. Rev Neurosci 2013, 24:71-88.
40. Nicot A., Ratnakar P.V., Ron Y., et al. Regulation of gene expression in experimental autoimmune encephalomyelitis indicates early neuronal dysfunction. Brain 2003, 126:398-412.
41. Zeis T., Kinter J., Herrero-Herranz E., et al. Gene expression analysis of normal appearing brain tissue in an animal model for multiple sclerosis revealed grey matter alterations, but only minor white matter changes. J Neuroimmunol 2008, 205:10-19.
42. Dutta R., McDonough J., Yin X. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006, 59:478-489.
43. Witte M.E., Nijland P.G., Drexhage J.A., et al. Reduced expression of PCG-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis. Acta Neuropathol 2013, 125:231-243.
44. Campbell G.R., Ziabreva I., Reeve A.K., et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol 2011, 69:481-492.
45. Campbell G.R., Mahad D.J. Clonal expansion of mitochondrial DNA deletions and the progression of multiple sclerosis. CNS Neurol Disord Drug Targets 2012, 11:589-597.
46. Kemp S., Berger J., Aubourg P. X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects. Biochim Biophys Acta 2012, 1822:1465-1474.
47. van Geel B.M., Bezman L., Loes D.J., et al. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol 2001, 49:186-194.
48. Galea E., Launay N., Portero-Otin M., et al. Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: A paradigm for multifactorial neurodegenerative diseases?. Biochim Biophys Acta 2012, 1822:1475-1488.
49. Ito M., Blumberg B.M., Mock D.J., et al. Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: Morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J Neuropathol Exp Neurol 2001, 60:1004-1019.
50. Hein S., Schönfeld P., Kahlert S., et al. Toxic effects of X-linked adrenoleukodystrophy-associated, very long chain fatty acids on glial cells and neurons from rat hippocampus in culture. Hum Mol Genet 2008, 17:1750-1761.
51. Schlüter A., Espinosa L., Fourcade S., et al. Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy. Hum Mol Genet 2012, 21:1062-1077.
52. Mirshafiey A., Mohsenzadegan M. Antioxidant therapy in multiple sclerosis. Immunopharmacol Immunotoxicol 2009, 31:13-29.
53. Schreibelt G., van Horssen J., van Rossum S., et al. Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Res Rev 2007, 56:322-330.
54. Linker R.A., Lee D.H., Ryan S., et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134:678-692.
55. Scannevin R.H., Chollate S., Jung M.Y., et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 2012, 341:274-284.
56. Talla V, Yu H, Chou ThH, et al: NADH-dehydrogenase type 2-suppressess irreversible visual loss and neurodegneration in the EAE animal model of MS. Mol Ther 2013 [Epub ahead of print].
57. Rice C.M., Sun M., Kemp K., et al. Mitochondrial sirtuins-A new therapeutic target for repair and protection in multiple sclerosis. Eur J Neurosci 2012, 35:1887-1893.
58. Su K.G., Banker G., Bourdette D., et al. Axonal degeneration in multiple sclerosis: The mitochondrial hypothesis. Curr Neurol Neurosci Rep 2009, 95:411-417.
59. Su K.G., Savino C., Marracci G., et al. Genetic inactivation of the p66 isoform of ShcA is neuroprotective in a murine model of multiple sclerosis. Eur J Neurosci 2012, 35:562-571.
60. Su K., Bourdette D., Forte M. Mitochondrial dysfunction and neurodegenertion in multiple sclerosis. Front Physiol 2013, 4:169.
61. Moreira P.I., Zhu X., Wang X., et al. Mitochondria: A therapeutic target in neurodegeneration. Biochim Biophys Acta 2010, 1802:212-220.
62. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326:818-823.
63. López-Erauskin J., Fourcade S., Galino J., et al. Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy. Ann Neurol 2011, 70:84-92.